Beijing Huayuan Academy of Biotechnology

Beijing Huayuan Academy of Biotechnology is a specialized biotechnology firm based in Beijing, China, dedicated to the advancement of regenerative medicine through stem cell research. The company primarily focuses on the development of umbilical cord-derived mesenchymal stem cell (UC-MSC) therapies for a broad range of indications, including spinal cord injury, liver cirrhosis, and type 2 diabetes. By leveraging its proprietary cell processing and cultivation technologies, the academy conducts clinical research in partnership with major Chinese medical institutions. Their mission centers on providing innovative cell-based solutions for previously untreatable degenerative diseases. The company is recognized for its early contributions to the standardization of stem cell research and its participation in national high-tech development programs.